CEO Davies considers possibilities

We are doing the wrong test

This isn’t really a sentence that early 2019 me would have foreseen myself writing but, here we are. I wish to propose a new paradigm for addressing novel global pandemics: serological (blood) testing for immunity. Such a standard is proactive, …

Read More »
Abstract Image

Making the case for the slower follower

By Anthony Davies

Considering the pace of the arms race for haemophilia therapies, the recently-announced collaboration between Novo and Bluebird feels quite late. Given what we know about their current progress, they’re unlikely to reach a long-term therapy first or …

Read More »

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.